NCT01152437 - A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 31, 2012

Conditions

Colorectal Neoplasms

Interventions

DRUG

BIBW 2992

Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management

DRUG

Cetuximab

Patients receive cetuximab intravenously, once a week, every week

Trial Locations (13)

1200.74.44001 Boehringer Ingelheim Investigational Site, Bournemouth

1200.74.44005 Boehringer Ingelheim Investigational Site, Bristol

1200.74.44006 Boehringer Ingelheim Investigational Site, Cambridge

1200.74.44003 Boehringer Ingelheim Investigational Site, Glasgow

1200.74.44009 Boehringer Ingelheim Investigational Site, London

1200.74.44012 Boehringer Ingelheim Investigational Site, Manchester

1200.74.44007 Boehringer Ingelheim Investigational Site, Northwood

1200.74.44013 Boehringer Ingelheim Investigational Site, Nottingham

1200.74.44011 Boehringer Ingelheim Investigational Site, Poole

1200.74.44010 Boehringer Ingelheim Investigational Site, Sheffield

1200.74.44008 Boehringer Ingelheim Investigational Site, Southampton

1200.74.44004 Boehringer Ingelheim Investigational Site, Sutton, Surrey

1200.74.44002 Boehringer Ingelheim Investigational Site, Truro